# Gwénaëlle Gravis

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/gwenaelle-gravis/

## Facts

| Field | Value |
| --- | --- |
| Citations | 24,351 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 66 |
| i10-index | 239 |
| Last Known Institution | Centre National de la Recherche Scientifique |
| OpenAlex ID | https://openalex.org/A5067036952 |
| ORCID iD | https://orcid.org/0000-0002-3127-1554 |
| Works | 725 |

## Researcher papers

- [Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial](https://scholariq.org/papers/prednisone-plus-cabazitaxel-or-mitoxantrone-for-metastatic-castration-resistant/)
- [Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma](https://scholariq.org/papers/sunitinib-alone-or-after-nephrectomy-in-metastatic-renal-cell-carcinoma/)
- [Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-alone-or-combined-with-chemotherapy-versus-chemotherapy-as-first/)
- [Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses](https://scholariq.org/papers/randomized-phase-iii-trial-of-dose-dense-methotrexate-vinblastine-doxorubicin/)
- [Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-metastatic-and-or/)

## Researcher topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)

## Researcher university

- [Centre National de la Recherche Scientifique](https://scholariq.org/institutions/centre-national-de-la-recherche-scientifique/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.